Skip to main content

Table 2 Percentage of cells expressing IHC detectable MMP3, -7 or -13 following incubation of tissue in standard medium, or medium supplemented with IL-1 or IL-1Ra for 48 hours

From: Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study

   

MMP3

MMP7

MMP13

   

Mean (percent)

SEM

Mean (percent)

SEM

Mean (percent)

SEM

Non-degenerate

NP

Untreated

0.9

1.0

4.2

2.1

2.7

0.9

  

IL-1

6.5

1.2

35.8

7.6

11.3

5.2

  

IL-1Ra

0

0.0

0.2

0.1

0.2

0.1

 

AF

Untreated

0.3

0.2

0.4

0.2

0.3

0.2

  

IL-1

1.2

0.5

1.9

0.9

1.5

0.5

  

IL-1Ra

0.0

0.0

0.2

0.1

0.0

0.0

Moderately degenerate

NP

Untreated

10.2

4.1

72.6

10.9

31.9

7.7

  

IL-1

14.1

5.6

83.4

10.1

38.2

10.7

  

IL-1Ra

0.0

0.0

3.3

1.2

2.7

1.1

 

AF

Untreated

1.9

0.9

3.5

1.1

1.0

0.4

  

IL-1

2.8

1.4

5.1

0.9

1.5

0.5

  

IL-1Ra

0.2

0.1

0.2

0.1

0.1

0.1

Severely degenerate

NP

Untreated

3.6

1.2

17.9

6.0

16.2

7.2

  

IL-1

6.5

3.1

19.4

6.5

19.9

6.3

  

IL-1Ra

0.2

0.1

2.2

1.1

2.1

1.2

 

AF

Untreated

2.0

0.4

0.9

0.4

0.2

0.1

  

IL-1

2.8

0.7

1.1

0.2

2.3

0.7

  

IL-1Ra

0.2

0.1

0.2

0.1

0.1

0.0

  1. AF, annulus fibrosus; IHC, immunohistochemistry; IL-1Ra, interleukin-1 receptor antagonist; MMP, matrix metalloproteinase; NP, nucleus pulposus; SEM, standard error of the mean.